Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Standardized Cannabis sativa extract attenuates tau and stathmin gene expression in the melanoma cell line.

Vaseghi G, Taki MJ, Javanmard SH.

Iran J Basic Med Sci. 2017 Oct;20(10):1178-1181. doi: 10.22038/IJBMS.2017.9398.

PMID:
29147495
2.

Review: The Role of Cannabinoids on Esophageal Function-What We Know Thus Far.

Gotfried J, Kataria R, Schey R.

Cannabis Cannabinoid Res. 2017 Oct 1;2(1):252-258. doi: 10.1089/can.2017.0031. eCollection 2017. Review.

3.

Cannabinoids Modulate Neuronal Activity and Cancer by CB1 and CB2 Receptor-Independent Mechanisms.

Soderstrom K, Soliman E, Van Dross R.

Front Pharmacol. 2017 Oct 10;8:720. doi: 10.3389/fphar.2017.00720. eCollection 2017. Review.

4.

Systematic review of the potential role of cannabinoids as antiproliferative agents for urological cancers.

Gandhi S, Vasisth G, Kapoor A.

Can Urol Assoc J. 2017 Mar-Apr;11(3-4):E138-E142. doi: 10.5489/cuaj.4371. Epub 2017 Apr 11. Review.

5.

A user's guide to cannabinoid therapies in oncology.

Maida V, Daeninck PJ.

Curr Oncol. 2016 Dec;23(6):398-406. doi: 10.3747/co.23.3487. Epub 2016 Dec 21. Review.

6.

Cannabidiol rather than Cannabis sativa extracts inhibit cell growth and induce apoptosis in cervical cancer cells.

Lukhele ST, Motadi LR.

BMC Complement Altern Med. 2016 Sep 1;16(1):335. doi: 10.1186/s12906-016-1280-0.

7.

Anticancer mechanisms of cannabinoids.

Velasco G, Sánchez C, Guzmán M.

Curr Oncol. 2016 Mar;23(2):S23-32. doi: 10.3747/co.23.3080. Epub 2016 Mar 16. Review.

8.

In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma.

Fisher T, Golan H, Schiby G, PriChen S, Smoum R, Moshe I, Peshes-Yaloz N, Castiel A, Waldman D, Gallily R, Mechoulam R, Toren A.

Curr Oncol. 2016 Mar;23(2):S15-22. doi: 10.3747/co.23.2893. Epub 2016 Mar 16.

9.

Simultaneous Activation of Induced Heterodimerization between CXCR4 Chemokine Receptor and Cannabinoid Receptor 2 (CB2) Reveals a Mechanism for Regulation of Tumor Progression.

Coke CJ, Scarlett KA, Chetram MA, Jones KJ, Sandifer BJ, Davis AS, Marcus AI, Hinton CV.

J Biol Chem. 2016 May 6;291(19):9991-10005. doi: 10.1074/jbc.M115.712661. Epub 2016 Feb 3.

10.

Lipid metabolic reprogramming in cancer cells.

Beloribi-Djefaflia S, Vasseur S, Guillaumond F.

Oncogenesis. 2016 Jan 25;5:e189. doi: 10.1038/oncsis.2015.49. Review.

11.

Potentiation of the antitumor activity of adriamycin against osteosarcoma by cannabinoid WIN-55,212-2.

Niu F, Zhao S, Xu CY, Sha H, Bi GB, Chen L, Ye L, Gong P, Nie TH.

Oncol Lett. 2015 Oct;10(4):2415-2421. Epub 2015 Jul 23.

12.

Fermented So-Cheong-Ryong-Tang (FCY) induces apoptosis via the activation of caspases and the regulation of MAPK signaling pathways in cancer cells.

Yim NH, Kim A, Jung YP, Kim T, Ma CJ, Ma JY.

BMC Complement Altern Med. 2015 Sep 24;15:336. doi: 10.1186/s12906-015-0821-2.

13.

Bone Cell-autonomous Contribution of Type 2 Cannabinoid Receptor to Breast Cancer-induced Osteolysis.

Sophocleous A, Marino S, Logan JG, Mollat P, Ralston SH, Idris AI.

J Biol Chem. 2015 Sep 4;290(36):22049-60. doi: 10.1074/jbc.M115.649608. Epub 2015 Jul 20.

14.

The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.

McAllister SD, Soroceanu L, Desprez PY.

J Neuroimmune Pharmacol. 2015 Jun;10(2):255-67. doi: 10.1007/s11481-015-9608-y. Epub 2015 Apr 28. Review.

15.

Targeting cannabinoid receptor-2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption.

Feng R, Tong Q, Xie Z, Cheng H, Wang L, Lentzsch S, Roodman GD, Xie XQ.

Mol Carcinog. 2015 Dec;54(12):1796-806. doi: 10.1002/mc.22251. Epub 2015 Jan 16.

16.

G protein-coupled receptors in stem cell maintenance and somatic reprogramming to pluripotent or cancer stem cells.

Choi HY, Saha SK, Kim K, Kim S, Yang GM, Kim B, Kim JH, Cho SG.

BMB Rep. 2015 Feb;48(2):68-80. Review.

17.

Guibitang, a traditional herbal medicine, induces apoptotic death in A431 cells by regulating the activities of mitogen-activated protein kinases.

Yim NH, Kim A, Liang C, Cho WK, Ma JY.

BMC Complement Altern Med. 2014 Sep 21;14:344. doi: 10.1186/1472-6882-14-344.

18.

Cannabinoids as therapeutic agents in cancer: current status and future implications.

Chakravarti B, Ravi J, Ganju RK.

Oncotarget. 2014 Aug 15;5(15):5852-72. Review.

19.

Antagonism of cannabinoid receptor 2 pathway suppresses IL-6-induced immunoglobulin IgM secretion.

Feng R, Milcarek CA, Xie XQ.

BMC Pharmacol Toxicol. 2014 Jun 9;15:30. doi: 10.1186/2050-6511-15-30.

20.

Involvement of PAR-4 in cannabinoid-dependent sensitization of osteosarcoma cells to TRAIL-induced apoptosis.

Notaro A, Sabella S, Pellerito O, Di Fiore R, De Blasio A, Vento R, Calvaruso G, Giuliano M.

Int J Biol Sci. 2014 Apr 8;10(5):466-78. doi: 10.7150/ijbs.8337. eCollection 2014.

Supplemental Content

Support Center